Characteristics of 18,014 Patients Undergoing Allogeneic BMT
| Characteristic . | No. of Patients . | Percent* . |
|---|---|---|
| Cohort | ||
| IBMTR, 1964-1990 | 14,041 | 77.9 |
| FHCRC, 1969-1992 | 3,973 | 22.1 |
| Female sex | 7,404 | 41.1 |
| Age at transplant (yr) | ||
| <10 | 2,623 | 14.6 |
| 10-19 | 3,929 | 21.8 |
| 20-29 | 4,654 | 25.8 |
| 30-39 | 4,191 | 23.3 |
| 40+ | 2,617 | 14.5 |
| Calendar year of transplant | ||
| 1964-1979 | 1,190 | 6.6 |
| 1980-1984 | 4,166 | 23.1 |
| 1985-1989 | 9,662 | 53.7 |
| 1990-1992 | 2,996 | 16.6 |
| Primary disease† | ||
| Acute nonlymphocytic leukemia | 5,065 | 28.1 |
| Chronic granulocytic leukemia | 4,770 | 26.5 |
| Acute lymphoblastic leukemia | 4,139 | 23.0 |
| Severe aplastic anemia | 2,114 | 11.7 |
| Other | 1,926 | 10.7 |
| Donor-recipient relationship and histocompatibility | ||
| HLA-identical sibling | 14,624 | 81.2 |
| 1 HLA-antigen mismatched sibling, relative | 1,356 | 7.5 |
| ≥2 HLA-antigen mismatched sibling, relative | 835 | 4.6 |
| Unrelated donor | 1,068 | 5.9 |
| Other, uncertain | 131 | 0.7 |
| Transplant conditioning regimen | ||
| TBI + Cy ± other drugs | 11,544 | 64.1 |
| TBI ± other drugs (no Cy) | 1,481 | 8.2 |
| LFI ± Cy ± other drugs | 655 | 3.6 |
| Busulfan + Cy ± other drugs | 2,775 | 15.4 |
| Cy ± other drugs | 1,391 | 7.7 |
| Other | 168 | 0.9 |
| T-cell depletion of marrow | ||
| No T-cell depletion | 15,518 | 86.1 |
| Anti-T or anti-T + NK MoAb | 1,255 | 7.0 |
| Sheep red blood cell rosetting | 166 | 0.1 |
| Lectins | 133 | 0.1 |
| CAMPATH-1 MoAb | 608 | 3.3 |
| Elutriation/density gradient centrifugation | 250 | 1.0 |
| Unclassified/other | 84 | 0.1 |
| Drugs given for GVHD prophylaxis | ||
| CsA + MTX (no ATG) | 6,659 | 37.0 |
| CsA (no MTX, no ATG) | 5,628 | 31.2 |
| MTX (no CsA, no ATG) | 3,871 | 21.5 |
| Any ATG | 525 | 2.9 |
| Other, none | 1,331 | 7.4 |
| Occurrence of acute GVHD II-IV | 7,063 | 39.2 |
| Treatment for acute GVHD II-IV | ||
| Steroids (No CsA, no ATG) | 3,285 | 18.2 |
| CsA + steroids (no ATG) | 1,776 | 9.9 |
| Any ATG | 1,101 | 6.1 |
| Other, none | 901 | 5.0 |
| Occurrence of extensive chronic GVHD‡ | 3,872 | 30.0 |
| Characteristic . | No. of Patients . | Percent* . |
|---|---|---|
| Cohort | ||
| IBMTR, 1964-1990 | 14,041 | 77.9 |
| FHCRC, 1969-1992 | 3,973 | 22.1 |
| Female sex | 7,404 | 41.1 |
| Age at transplant (yr) | ||
| <10 | 2,623 | 14.6 |
| 10-19 | 3,929 | 21.8 |
| 20-29 | 4,654 | 25.8 |
| 30-39 | 4,191 | 23.3 |
| 40+ | 2,617 | 14.5 |
| Calendar year of transplant | ||
| 1964-1979 | 1,190 | 6.6 |
| 1980-1984 | 4,166 | 23.1 |
| 1985-1989 | 9,662 | 53.7 |
| 1990-1992 | 2,996 | 16.6 |
| Primary disease† | ||
| Acute nonlymphocytic leukemia | 5,065 | 28.1 |
| Chronic granulocytic leukemia | 4,770 | 26.5 |
| Acute lymphoblastic leukemia | 4,139 | 23.0 |
| Severe aplastic anemia | 2,114 | 11.7 |
| Other | 1,926 | 10.7 |
| Donor-recipient relationship and histocompatibility | ||
| HLA-identical sibling | 14,624 | 81.2 |
| 1 HLA-antigen mismatched sibling, relative | 1,356 | 7.5 |
| ≥2 HLA-antigen mismatched sibling, relative | 835 | 4.6 |
| Unrelated donor | 1,068 | 5.9 |
| Other, uncertain | 131 | 0.7 |
| Transplant conditioning regimen | ||
| TBI + Cy ± other drugs | 11,544 | 64.1 |
| TBI ± other drugs (no Cy) | 1,481 | 8.2 |
| LFI ± Cy ± other drugs | 655 | 3.6 |
| Busulfan + Cy ± other drugs | 2,775 | 15.4 |
| Cy ± other drugs | 1,391 | 7.7 |
| Other | 168 | 0.9 |
| T-cell depletion of marrow | ||
| No T-cell depletion | 15,518 | 86.1 |
| Anti-T or anti-T + NK MoAb | 1,255 | 7.0 |
| Sheep red blood cell rosetting | 166 | 0.1 |
| Lectins | 133 | 0.1 |
| CAMPATH-1 MoAb | 608 | 3.3 |
| Elutriation/density gradient centrifugation | 250 | 1.0 |
| Unclassified/other | 84 | 0.1 |
| Drugs given for GVHD prophylaxis | ||
| CsA + MTX (no ATG) | 6,659 | 37.0 |
| CsA (no MTX, no ATG) | 5,628 | 31.2 |
| MTX (no CsA, no ATG) | 3,871 | 21.5 |
| Any ATG | 525 | 2.9 |
| Other, none | 1,331 | 7.4 |
| Occurrence of acute GVHD II-IV | 7,063 | 39.2 |
| Treatment for acute GVHD II-IV | ||
| Steroids (No CsA, no ATG) | 3,285 | 18.2 |
| CsA + steroids (no ATG) | 1,776 | 9.9 |
| Any ATG | 1,101 | 6.1 |
| Other, none | 901 | 5.0 |
| Occurrence of extensive chronic GVHD‡ | 3,872 | 30.0 |
Abbreviations: IBMTR, International Bone Marrow Transplant Registry; FHCRC, Fred Hutchinson Cancer Research Center; TBI, total-body irradiation; Cy, cyclophosphamide; LFI, limited-field irradiation; CsA, cyclosporine; MTX, methotrexate; GVHD, graft-versus-host disease; NK, natural killer cells; MoAb, monoclonal antibody; ATG, antithymocyte globulin.
Percents do not always add to 100% because of rounding.
Primary diseases excluded were non-Hodgkin’s lymphomas (n = 729), Fanconi’s anemia (n = 201), and immune deficiency diseases (n = 376). Other primary diseases included Hodgkin’s disease (n = 163), other malignancies (n = 347), myelodysplastic syndromes or myeloproliferative disorders (n = 632), and other smaller groups of primarily nonmalignant diseases (n = 784), including inherited disorders of metabolism (n = 158), and hemoglobinopathies (n = 315).
Occurrence of extensive chronic GVHD among 13,107 patients who survived ≥90 days posttransplant.